pyrazines has been researched along with Metastase in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 20 (51.28) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, MJ; Cantarini, M; Cho, BC; Frewer, P; Han, JY; Kim, SW; Kowalski, D; Lee, JS; Mellemgaard, A; Orlov, S; Ottesen, L; Ou, X; Oxnard, G; Sequist, LV; Su, WC; Verheijen, RB; Yang, JC; Yu, H | 1 |
| Bamodu, OA; Chao, TY; Haryana, SM; Hsiao, M; Hsu, WM; Liu, YL; Pikatan, NW; Yeh, CT | 1 |
| Alva, AS; Appleman, LJ; Bitman, B; Burke, JM; Cetnar, J; Chan, C; Fleming, MT; George, DJ; Hahn, NM; Harrison, MR; Izumi, R; Milowsky, MI; Mortazavi, A; Munugalavadla, V; O'Donnell, PH; Patel, P; Schmidt, EV; Shore, N; Sonpavde, GP; Staats, J; Weinhold, KJ; Zhang, T | 1 |
| Abel, L; Baschnagel, AM; Clark, PA; Elnaggar, JH; Kaushik, S; Kimple, RJ; Kromke, AC; Leal, TA; Longhurst, CA; Nickel, KP; Skiba, JH; VanBeek, HJ; Zhao, SG | 1 |
| Markham, A | 1 |
| Huang, Z; Ji, Y; Lai, Y; Liu, J; Tian, J; Xu, J; Yan, C; Zhang, Y; Zhao, D; Zou, Y | 1 |
| Barata, P; Cooney, M; Dreicer, R; Garcia, JA; Tyler, A; Wright, J | 1 |
| Frigault, MM; Gan, HK; Hua, Y; Lickliter, JD; Millward, M; Morgan, S; Qi, C; Sai, Y; Su, W; Wang, J; Yang, L; Zhang, L | 1 |
| Brooks, TR; Carson, WE; Dao, TV; Grignol, VP; Hade, EM; Kendra, KL; Kondalasula, SV; Lesinski, GB; Luedke, EA; Markowitz, J; Mundy-Bosse, BL; Olencki, T; Paul, BK | 1 |
| Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR | 1 |
| Buchner, K; Eulberg, D; Facchetti, F; Ghobrial, IM; Klussmann, S; Kruschinski, A; Lonardi, S; Maasch, C; Maiso, P; Mishima, Y; Moschetta, M; Purschke, WG; Reagan, MR; Roccaro, AM; Rossi, G; Sacco, A; Ungari, M; Vater, A; Vonhoff, S; Zboralski, D; Zöllner, S | 1 |
| Hengstler, JG; Schad, A; Schmidt, M; Sleeman, JP; Thaler, S; Thiede, G | 1 |
| Baudin, E; Berruti, A; Chen, J; Choueiri, TK; Demeure, MJ; Fassnacht, M; Fleege, T; Gilbert, J; Haak, H; Hammer, GD; Hesseltine, E; Kroiss, M; Poondru, S; Quinn, DI; Ronchi, CL; Rorig, R; Stephens, AW; Terzolo, M; Worden, F | 1 |
| Kirschner, LS | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Kasaoka, T; Nakajima, M; Nishiyama, H; Okada, M | 1 |
| Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Richards, T; Weber, D | 1 |
| Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ | 1 |
| Capanu, M; Holen, KD; Ilson, DH; Kelsen, DP; Kemeny, MM; Kindler, HL; Power, DG; Shah, MA; Tang, L; Wright, JJ | 1 |
| Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS | 1 |
| Argiris, A; Axelrod, RS; Burtness, B; Deconti, RC; Forastiere, AA; Ghebremichael, M | 1 |
| Bale, RJ; Eisterer, W; Gabriel, M; Gastl, G; Kendler, D; Kroiss, A; Madleitner, R; Putzer, D; Uprimny, C; Virgolini, IJ | 1 |
| Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK | 1 |
| Abbruzzese, JL; Baker, C; Chiao, PJ; Dong, QG; Evans, DB; Frederick, WA; Fujioka, S; Schmidt, C; Sclabas, GM | 1 |
| Ansari, RH; Davis, NB; George, C; Ryan, CW; Stadler, WM; Taber, DA; Vogelzang, NJ; Vokes, EE | 1 |
| Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D | 1 |
| Antonescu, CR; Kraft, AS; Maki, RG; Scheu, K; Schwartz, GK; Wadler, S; Wright, JJ; Yamada, J | 1 |
| Birle, D; Degendorfer, P; Hedley, D; Mackay, H; Mackenzie, M; Major, P; Moore, M; Nicklee, T; Oza, A; Siu, L; Townsley, C; Tsao, MS; Vincent, M; Wright, J | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Kondagunta, GV; Motzer, RJ; Ronnen, EA | 1 |
| Laurie, SA; Licitra, L | 1 |
| Degendorfer, P; Gomez-Abuin, G; Moore, MJ; Pond, G; Stadler, WM; Winquist, E; Wright, J | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Balcerzak, SP; Galloway, S; Kraut, EH; Moore, T; Thomas, JP; Vandre, DD | 1 |
4 review(s) available for pyrazines and Metastase
| Article | Year |
|---|---|
Savolitinib: First Approval.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; China; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Approval; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pyrazines; Stomach Neoplasms; Triazines | 2021 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
21 trial(s) available for pyrazines and Metastase
| Article | Year |
|---|---|
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Salvage Therapy; Survival Rate; Triazines | 2020 |
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Urologic Neoplasms | 2020 |
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Topics: Aged; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin | 2018 |
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Topics: Biomarkers, Tumor; Drug Monitoring; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Treatment Outcome; Triazines | 2019 |
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytokines; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrazines; Recombinant Proteins; Treatment Outcome | 2014 |
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.
Topics: Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Placebos; Protein Kinase Inhibitors; Pyrazines | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis | 2010 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms | 2010 |
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Protease Inhibitors; Pyrazines; Stomach Neoplasms; Treatment Outcome | 2011 |
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Recurrence; Survival Analysis | 2011 |
First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Quality of Life; Thyroid Neoplasms; Treatment Failure | 2012 |
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cysteine Endopeptidases; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Multienzyme Complexes; Neoplasm Metastasis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome | 2004 |
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2004 |
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Drug Administration Schedule; Fatigue; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2005 |
A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Carbonic Anhydrase IX; Carbonic Anhydrases; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver; Male; Microcirculation; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serine; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pyrazines; Survival Analysis; Urologic Neoplasms; Urothelium | 2007 |
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Carcinoma, Small Cell; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pyrazines; Pyridines | 2002 |
14 other study(ies) available for pyrazines and Metastase
| Article | Year |
|---|---|
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Carcinogenesis; Caspase 3; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neuroblastoma; Phenotype; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Spheroids, Cellular; STAT3 Transcription Factor | 2020 |
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Female; Heterografts; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2021 |
Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Colorectal Neoplasms; Dioxolanes; Epithelial-Mesenchymal Transition; HCT116 Cells; Humans; Mice; Neoplasm Metastasis; Pyrazines; Reactive Oxygen Species; Solubility; Structure-Activity Relationship | 2018 |
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas.
Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms | 2013 |
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Metastasis; Oligonucleotides; Polyethylene Glycols; Pyrazines | 2014 |
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prognosis; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Inhibition of IGF-1R in adrenocortical carcinoma.
Topics: Adrenocortical Carcinoma; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Pyrazines | 2015 |
Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.
Topics: Animals; Hydroxamic Acids; Lung Neoplasms; Male; Matrix Metalloproteinase Inhibitors; Melanoma, Experimental; Mice; Neoplasm Metastasis; Protease Inhibitors; Pyrazines; Sulfonamides | 2008 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2010 |
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines | 2012 |
Function of nuclear factor kappaB in pancreatic cancer metastasis.
Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Phenotype; Pyrazines; Retroviridae; Time Factors; Tumor Cells, Cultured | 2003 |
Medullary renal cell carcinoma and response to therapy with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Humans; Kidney Medulla; Kidney Neoplasms; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2006 |